

February 20, 2020

The Manager- Listing  
**BSE Limited**  
Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai - 400001

The Manager- Listing  
**National Stock Exchange of India Limited**  
Exchange plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra –Kurla Complex, Bandra (E),  
Mumbai - 400051

Dear Sir(s),

**Subject: Launch of FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (QTERN®)**

We refer to our communication dated September 25, 2019 intimating the receipt of Import and Market Permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (QTERN®).

With regard to the same, we now wish to further update that AstraZeneca Pharma India Limited has commenced the launch of QTERN® in India.

FDC of Dapagliflozin 10mg + Saxagliptin 5mg is indicated as an adjunct to diet and exercise to improve glycemc control in adults with type 2 diabetes mellitus (T2DM).

We request you to kindly take the same on record.

For **AstraZeneca Pharma India Limited**



**Pratap Rudra**  
Company Secretary & Legal Counsel

